Setmelanotide

Setmelanotide (RM-493) is a selective melanocortin 4 receptor (MC4R) agonist with EC50s of 0.27 nM and 0.28 nM for human and rat MC4R, respectively[1].

Product Specifications

CAS Number

[920014-72-8]

Product Name Alternative

RM-493; BIM-22493; IRC-022493

UNSPSC

12352209

Hazard Statement

H302, H315, H319, H335

Target

Melanocortin Receptor

Type

Peptides

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Metabolic Disease; Endocrinology

Assay Protocol

https://www.medchemexpress.com/Setmelanotide.html

Concentration

10mM

Purity

99.93

Solubility

H2O : 62.5 mg/mL (ultrasonic)

Smiles

O=C(N[C@@H](CSSC[C@](C(N[C@@H]1C)=O)([H])NC([C@@H](NC(C)=O)CCCNC(N)=N)=O)C(N)=O)[C@@H](NC([C@@H](NC([C@@](NC([C@@H](NC1=O)CC2=CN=CN2)=O)([H])CC3=CC=CC=C3)=O)CCCNC(N)=N)=O)CC4=CNC5=CC=CC=C45

Molecular Formula

C49H68N18O9S2

Molecular Weight

1117.31

Precautions

H302, H315, H319, H335

References & Citations

[1]Kumar KG, et al. Analysis of the therapeutic functions of novel melanocortin receptor agonists in MC3R- and MC4R-deficient C57BL/6J mice. Peptides. 2009 Oct;30 (10) :1892-900.|[2]Kievit P, et al. Chronic treatment with a melanocortin-4 receptor agonist causes weight loss, reduces resistance, and improves cardiovascular function in diet-induced obese rhesus macaques. Diabetes. 2013 Feb;62 (2) :490-7.